Navigation Links
Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?
Date:10/28/2008

Research to be presented Sunday, November 2, 2008 at this year's liver

meeting in San Francisco, California, October 31 - November 4

SAN FRANCISCO, Oct. 28 /PRNewswire/ -- Researchers from the Michael E. DeBakey VA Medical Center, led by Jennifer Kramer, Ph.D., looked at a population of U.S. veterans to determine the patient, provider, and facility characteristics that determined how likely after diagnosis for hepatitis C virus patients who have HIV are treated for HCV. This retrospective study used the Hepatitis C Clinical Case Registry to identify patients who had both infections and who had visited a VA facility at least twice in a six-year period. "This is a very large cohort (N=7,103) of patients with laboratory confirmed HCV-HIV coinfection (maybe one of the largest ever examined) that is very representative of VA users," said Dr. Kramer, but she cautions, "It is difficult to draw conclusions to all patients with HCV-HIV coinfection because the VA cohort tends to be predominately male and relatively low income."

Of those patients in the registry who had HCV and HIV, 10.3% were treated within two years of HCV diagnosis. The researchers went on to identify the factors that resulted in treatment for those patients. Race was a patient factor that determined who was more likely to be treated for HCV. Patients who were black or Hispanic were not as likely to be treated as compared to white patients after HCV diagnosis. Other determining factors were sex (males weren't as likely to be treated as females), drug use, psychosis, high HIV viral load, and genotype 1 or 4. Patients were more likely to be treated if they were diagnosed with HCV more recently; were also diagnosed with cirrhosis; and had high CD4 counts, hemoglobin, and persistently high liver enzyme scores.

The study's authors also identified provider and facility characteristics that determined if a patient who also had HIV was treated for HCV. Patients were more likely to be treated if the facility in which they were seen had only one inpatient hospital compared to those with multiple sites and if the provider was a specialist for HCV.

"The study highlights the important role of facilities and providers, in addition to the known patient-related factors, in explaining variation and possibly outcomes of care in HCV-infected patients," said Hashem El-Serag, MD. "These factors have been largely ignored in current research. We plan to investigate the role of facility factors in HCV treatment receipt in coinfected patients further by including data from a recently completed facility survey addressing facility factors specifically involved in HCV care."

Abstract title:

Patient, provider, and facility characteristics of HCV antiviral treatment among US veterans with HCV-HIV coinfection.

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting, held in San Francisco, California, October 31 - November 4, will bring together more than 7,000 researchers from 55 countries.

A pressroom will be available from November 1 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Tracy at 703-299-9766.

Press releases and all abstracts are available online at http://www.aasld.org .

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com


'/>"/>
SOURCE American Association for the Study of Liver Diseases
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Whether combat or peacekeeping, PTSD impacts veterans well-being
2. New SEIU Television Ad: Thelma Drake is Wrong for Veterans, Wrong For Virginia
3. Kaiser Permanente and Veterans Affairs Preview Electronic Health Record Interoperability to Enable Better Health Care
4. Historic Legislation to End Delays in Veterans Health Care Funding
5. Survey Shows Most Americans Want Government to Stand Up for Veterans
6. Helping Veterans in Our Communities
7. Drinking Problems Greater Among Returning Combat Veterans
8. Researchers probe geographical ties to ALS cases among 1991 Gulf War veterans
9. Veterans Mourn the Passing of Dr. Michael DeBakey
10. Summit Brings Renewed VA Drive for Women Veterans
11. Purple Dog Tag Launches; Provides Hope and Healing to Thousands of US Servicemen & Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry ... educational webinar, they will present the line of epMotion automated liquid handling system. ... you can automate everyday pipetting tasks. , Ideal for scientists and lab technicians ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston area ... Texas, is launching a regional charity effort to provide publicity assistance and generate ... Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that has ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... Boca Raton (PRWEB) , ... August 18, 2017 , ... ... is continuing to ramp up its marketing efforts with its product now available through ... hangover remedy to the public. The effervescent powdered drink is designed to quickly detox ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
Breaking Medicine Technology: